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Introduction
BRAF or NRAS are the most commonly mutated protooncogenes in melanoma with~50% of melanomas expressing mutationally activated BRAF V600E and 25-30% expressing mutationally activated NRAS (Brose et al., 2002; Cancer Genome Atlas, 2015; Davies et al., 2002; Hodis et al., 2012; Holderfield et al., 2014) . BRAF (>80%) and NRAS (~14%) mutations are also present at a high frequency in pigmented nevi; however, these melanocytic lesions are generally benign, rarely progress to melanoma, and display hallmarks of a senescence-like growth arrest (Michaloglou et al., 2005; Mooi and Peeper, 2006; Pollock et al., 2003) . Thus, BRAF-or NRAS-mediated conversion of normal melanocytes to malignant melanoma cells requires additional cooperating events (Brose et al., 2002; Cancer Genome Atlas, 2015; Davies et al., 2002; Hodis et al., 2012; Shain et al., 2015; Shull et al., 2012) .
Aberrant PI3 0 -lipid accumulation is a common mechanism of melanoma progression, and there are several ways in which PI3 0 -lipid signaling may be elevated in melanoma (Cancer Genome Atlas, 2015; Chin et al., 1998; Goel et al., 2006; Haluska et al., 2006; Hodis et al., 2012; Shull et al., 2012; Vredeveld et al., 2012) . These include silencing of the PTEN, INPP4B, or PIB5PA lipid phosphatases, mutational activation of PIK3CA or RAC1, which can activate PI3Ka or PI3Kb, respectively, or mutational activation of the PI3 0 -lipid effector kinases AKT1 or AKT3 (Cancer Genome Atlas, 2015; Chi et al., 2015; Hodis et al., 2012; Perez-Lorenzo et al., 2013; Shull et al., 2012; Ying et al., 2003) . Although PTEN silencing is common in melanoma, mutational activation of PIK3CA is rare, despite the ability of activated PIK3CA
H1047R to promote progression of BRAF V600E -initiated melanomas in mouse models and the high frequency of the PIK3CA mutation in other types of cancer (Cancer Genome Atlas 2015; Curtin et al., 2006; Deuker et al., 2015; Hodis et al., 2012; Marsh Durban et al., 2013; Omholt et al., 2006; Samuels and Velculescu, 2004) . As mutationally activated NRAS is reported to simultaneously activate both RAFand PI3K-mediated signaling, silencing of PTEN or mutational activation of PIK3CA occurs rarely in NRAS-mutated melanomas (Cancer Genome Atlas, 2015; Curtin et al., 2006; Hodis et al., 2012; Kim et al., 2012; Shull et al., 2012; Tsao et al., 2004) . Furthermore, both the TCGA and Broad Institute genome sequencing analyses of melanoma samples were utilized to examine the frequency of co-existing mutations in PIK3CA plus BRAF or NRAS in melanoma. The TCGA analysis revealed that, 13 of 287 (5%) melanoma tumor samples sequenced displayed an alteration in PIK3CA (Cerami et al., 2012; Gao et al., 2013) . Of these 13 alterations, two were copy number gains (gene amplifications), three were known driver mutations, seven were variants of unknown significance, and one was a homozygous deletion (Cerami et al., 2012; Gao et al., 2013) . Similarly, the Broad Institute analysis of 121 melanoma specimens also revealed a PIK3CA mutation frequency of 5% (six of 121) (Cerami et al., 2012; Gao et al., 2013) . Of the six mutations identified in PIK3CA from the Broad Institute analysis, five are ascribed as driver mutations, and one is a variant of unknown significance (Cerami et al., 2012; Gao et al., 2013) . The vast majority of PIK3CA mutations cooccurred with either a BRAF or a NRAS mutation, but this is not surprising as mutational alterations of BRAF or NRAS were detected at a frequency of 81 or 86% in melanoma samples from the TCGA and Broad Institute analyses, respectively (Cerami et al., 2012; Gao et al., 2013) . Hence, these data indicate that melanoma with coexisting mutations in PIK3CA plus BRAF or NRAS represent a small, but relevant subset.
In BRAF-mutated melanoma cell lines, BRAF V600E and PI3 0 -lipid signaling cooperate to regulate melanoma proliferation through AKT-independent, mTORC1-dependent effects on protein synthesis (Dankort et al., 2009; Deuker et al., 2015; Marsh Durban et al., 2013; . Therefore, to further assess the role of PI3K signaling in melanoma, we employed PIK3CA-mutated cell lines derived from chemo-na€ ıve metastatic melanoma patients (NZM40: NRAS  Q61H /PIK3CA  H1047R ; NZM52:  BRAF  V600E /PIK3CA   H1047R   ; and NZM91: PIK3CA   E545K ) (Kim et al., 2012) . These cell lines were used to examine the contribution of mutationally activated p110a PI3K to melanoma cell signaling, proliferation, and tumorigenesis by interrogating the pathway with a panel of pharmacological PI3K inhibitors. We observed that combined inhibition of MEK1/2 and PI3K signaling elicited more potent antiproliferative effects and greater suppression of S-phase progression of the cell cycle compared with single-agent inhibition of either pathway alone. Similarly, pharmacological inhibition of mTORC1/2 also displayed substantial antiproliferative effects on PIK3CA-mutated melanoma cells. Surprisingly, BRAF V600E /PIK3CA H1047R mutant melanoma cell proliferation was largely resistant to BRAF V600E inhibition despite the profound inhibition of S-phase progression in these cells, which may be a consequence of reactivation of MAPK signaling. Thus, these data support the rationale that the maintenance of PIK3CA-mutated melanoma cells depends on the ability of MEK1/2 and PI3K signaling to cooperatively regulate mTORC1.
Results
Cooperative regulation of cell proliferation by MEK1/ 2 and PI3K signaling in PIK3CA-mutated melanoma cells To determine the dependency of PIK3CA-mutated melanoma cells on MAPK and PI3K signaling, we examined the effects of pharmacological blockade of MEK1/2 or the differential effects of structurally unrelated, mechanistically dissimilar PI3K inhibitors using human melanoma-derived cell lines that were generated from metastatic melanoma patients in New Zealand (NZM40, NZM52, and NZM91; Tables S1 and S2) (Kim et al., 2012) . The NZM40, NZM52, and NZM91 cell lines were selected based solely on their reported PIK3CA mutational status: NZM40 and NZM52 cells express PIK3CA H1047R and NZM91 cells express PIK3CA E545K , both of which are gain-of-function forms of PI3 0 -kinase-a (Kim et al., 2012) . In addition, NZM40 cells express NRAS Q61H and the NZM52 cell line expresses BRAF V600E , the latter a combination of genetic abnormalities that we have examined in genetically engineered mouse (GEM) models (Deuker et al., 2015; Kim et al., 2012) . Hybridization-based target enrichment and sequencing of approximately 500 cancer genes confirmed mutational activation of NRAS, BRAF, or PIK3CA in the relevant cell lines, but failed to identify an oncogenic driver of RAS?RAF?MEK1/2?ERK1/2 MAP kinase signaling in NZM91 cells, including no evidence of bi-allelic loss of NF1.
To assess the effects of MEK1/2 or PI3K inhibition, NZM40, NZM52, and NZM91 cells were treated with inhibitors of MEK1/2 (5 lM GDC-0973/MEKi 1 ), class I PI3K (5 lM GDC-0941/PI3Ki 1 ; inhibits PI3Ka, PI3Kb, PI3Kd, and PI3Kc), b-sparing PI3K (5 lM GDC-0032/ PI3Ki 2 ; inhibits PI3Ka, PI3Kd, and PI3Kc) or PI3Ka (5 lM BYL-719/PI3Kai; selectively inhibits PI3Ka), either as single agents or in combination, for 3-8 days, with viable cells fixed and stained using crystal violet ( Figure 1A ). Single-agent inhibition of MEK1/2, PI3Ka, b-sparing PI3K, or class I PI3K led to suppression of proliferation of all three cell lines. Class I PI3K inhibition elicited the most potent antiproliferative effects against NZM40 and NZM91 cells, whereas single-agent inhibition of class I PI3K or b-sparing PI3K inhibited NZM52 proliferation to a similar extent. Of the various PI3K inhibitors tested, the PI3Ka inhibitor displayed the least potent antiproliferative effects against all three cell lines. Importantly, the combined inhibition of MEK1/2 plus class I PI3K, bsparing PI3K, or PI3Ka displayed enhanced antiproliferative effects in all three cell lines compared with the corresponding single agents.
To test whether mutationally activated PIK3CA contributes to S-phase progression, NZM cells were treated with inhibitors of MEK1/2 (5 lM GDC-0973/MEKi 1 ), class I PI3K (5 lM GDC-0941/PI3Ki 1 ), or PI3Ka (5 lM BYL-719/PI3Kai), either alone or in combination, for 48 h with cells labeled with BrdU for the last 24 h of the treatment and analyzed by flow cytometry ( Figure 1B ). MEK1/2 inhibition significantly reduced BrdU incorporation in all three cell lines (NZM40: P < 0.01; NZM52 and NZM91: P < 0.0005) in a manner consistent with the decrease in proliferation observed following MEK1/2 inhibition (Figure 1A) . Perhaps surprisingly, treatment of NZM40 cells with either a PI3Ka or class I PI3K inhibitor had only modest effects on BrdU incorporation, even though these inhibitors displayed potent antiproliferative effects in these cells ( Figure 1A, B) . By contrast, treatment of NZM91 cells with either a PI3Ka or class I PI3K inhibitor significantly decreased BrdU incorporation (PI3Ka: P < 0.005; class I PI3K: P < 0.0001) in accordance with the antiproliferative effects of these inhibitors in this cell line ( Figure 1A, B) . Strikingly, in NZM52 cells, PI3Ka inhibition more potently suppressed S-phase progression compared to class I PI3K inhibition, whereas class I PI3K inhibition resulted in a greater inhibitory effect on NZM52 proliferation ( Figure 1A, B) . Importantly, combined inhibition of MEK1/2 plus either PI3Ka or class I PI3K inhibition led to a more profound reduction in BrdU incorporation (>86% decrease) compared with the corresponding single agents in all three NZM cell lines, which was analogous to the antiproliferative effects observed with these combined treatments ( Figure 1A , B). Hence, these data indicate that MEK1/2 and PI3 0 -lipid signaling cooperate to regulate PIK3CA-mutated melanoma cell proliferation through S-phase of the cell division cycle.
To examine the consequences on intracellular signaling of single-agent versus combined MEK1/2 or PI3K inhibition on the NZM melanoma cell lines, cells were treated with inhibitors of MEK1/2 (5 lM GDC-0973/MEKi 1 ), class I PI3K (5 lM GDC-0941/PI3Ki 1 ), b-sparing PI3K (5 lM GDC-0032/PI3Ki 2 ), or PI3Ka (5 lM BYL-719/PI3Kai), either alone or in combination, for 24 h with extracts analyzed by immunoblotting ( Figure 1C ). As expected, MEK1/2 inhibition led to decreased ERK1/2 phosphorylation (P-ERK1/2 Thr202/Tyr204) with little or no effect on AKT phosphorylation (P-AKT Ser473). Conversely, class I PI3K, b-sparing PI3K, or PI3Ka inhibition resulted in reduced P-AKT and its direct downstream target, P-PRAS40 (Thr246) with largely no effect on P-ERK1/2. Strikingly, MEK1/2 inhibition had little or no effect on the phosphorylation of the mTOR Complex I (mTORC1) downstream effectors, ribosomal protein (rp) S6 (P-rpS6 Ser235/236 and Ser240/244) and 4E-BP1 (P-4EBP1 Thr37/46 and Ser65), despite inhibition of P-p70 S6K (Thr389), the upstream kinase of rpS6. The lack of efficacy of the MEK1/2 inhibitor to reduce P-rpS6 or P-4E-BP1 in NZM52 (BRAF V600E , PIK3CA H1047R ) cells stands in contrast to the potent inhibitory effects of MEK1/2 inhibition on P-rpS6 and P-4E-BP1 in BRAFmutated cells as previously reported . Single-agent inhibition of class I PI3K, b-sparing PI3K, or PI3Ka led to decreased P-rpS6 and P-4E-BP1, but this occurred in the absence of any changes of P-p70 S6K in NZM40 and NZM91 cells. Class I PI3K or b-sparing PI3K also reduced P-rpS6 and P-4E-BP1 without altering Pp70 S6K in NZM52 cells. However, inhibition of PI3Ka had little or no effect on P-p70 S6K , P-rpS6, or P-4E-BP1 in NZM52 cells. Combined MEK1/2 plus class I PI3K, bsparing PI3K, or PI3Ka inhibition more potently suppressed P-rpS6 compared with the action of the various single agents in all NZM cell lines. Although combined inhibition of MEK1/2 and class I PI3K, b-sparing PI3K, or PI3Ka led to a greater reduction in P-4E-BP1 in NZM52 cells, these combined treatments were ineffective in further decreasing P-4E-BP1 in NZM40 or NZM91 cells compared to any of the three PI3K inhibitors. Taken together, these data suggest that MEK1/2 and PI3K signaling cooperate to regulate the mTORC1 signaling axis through the phosphorylation of rpS6 and 4E-BP1, which in turn may contribute to the proliferation of PIK3CA-mutated melanoma cells.
H1047R -mutated melanoma cells Previous analyses demonstrated the sensitivity of BRAFmutated melanoma cells to BRAF V600E inhibition, and consequently, we tested the effects of BRAF V600E inhibition on NZM52 proliferation and signaling (Deuker et al., 2015; Marsh Durban et al., 2013; . NZM52 cells were treated with inhibitors of BRAF ), or PI3Ka (5 lM BYL-719/PI3Kai), either alone or in combination, with viable cells stained using crystal violet ( Figure 2A ). To our surprise, neither single-agent nor combined inhibition of BRAF V600E or PI3Ka displayed antiproliferative activity against these cells. Class I PI3K inhibition significantly suppressed NZM52 proliferation, while the combined inhibition of BRAF V600E and class I PI3K did not further reduce proliferation compared to single-agent treatment. These results differ from previous analyses, in which combined inhibition of BRAF V600E and class I PI3K more profoundly inhibited BRAF-mutated melanoma proliferation compared to their corresponding single agents (Deuker et al., 2015; .
To examine the effect of combined inhibition of BRAF V600E and PI3Ka on NZM52 intracellular signaling, NZM52 cells were treated with BRAF V600E (100 nM LGX-818/BRAFi) or PI3Ka (5 lM BYL-719/PI3Kai) inhibitors, either alone or in combination, for 24 h with cell lysates analyzed by immunoblotting ( Figure 2B ). Although BRAF V600E inhibition led to decreased P-ERK1/2, there was substantial residual P-ERK1/2 after 24 h of drug treatment in these cells. As observed previously, inhibition of BRAF V600E had little or no effect on P-AKT, but suppressed P-p70
S6K
. Inhibition of PI3Ka reduced P-AKT and P-PRAS40 with little or no effect on P-p70 S6K . Singleagent or combined inhibition of BRAF V600E or PI3Ka had no discernible inhibitory effect on P-rpS6 or P-4E-BP1 in NZM52 cells.
To determine whether the residual P-ERK1/2 detected in NZM52 cells following inhibition of BRAF V600E may reflect reactivation of the MAPK pathway, NZM52 cells were treated with the BRAF V600E inhibitor (100 nM LGX-818/BRAFi) for 4, 10, or 18 h with extracts analyzed by immunoblotting ( Figure 2C ). BRAF V600E inhibition led to decreased P-ERK1/2 at 4 h, but by 10 h P-ERK1/2 levels began to increase with a substantial rebound in P-ERK1/2 at 18 h. These data suggest that in NZM52 cells, inhibition of BRAF V600E initially suppresses BRAF V600E ? MEK1/2?ERK1/2 signaling, but eventually leads to a substantial rebound in P-ERK1/2, as previously observed in other contexts as in BRAF T1799A -mutated colorectal or thyroid cancer cell lines (Montero-Conde et al., 2013; Sun et al., 2014) . These data may also explain the lack of profound antiproliferative activity of single-agent BRAF V600E inhibition in NZM52 cells. The striking inability of the BRAF V600E inhibitor to suppress the proliferation of NZM52 cells and to sustain inhibition of P-ERK1/2 was somewhat surprising based on previous demonstrations of the sensitivity of BRAFmutated melanoma cells to BRAF V600E inhibitors (Deuker et al., 2015; Marsh Durban et al., 2013; . Thus, we sought to test the effects of BRAF V600E inhibition on S-phase progression of NZM52 cells. To that end, NZM52 cells were treated with a BRAF V600E inhibitor (100 nM LGX-818/BRAFi) for 48 h with cells incubated with BrdU for the last 24 h of drug treatment. S-phase progression was assessed by flow cytometric analysis of BrdU incorporation ( Figure 2D ). BRAF V600E inhibition significantly reduced BrdU incorporation by approximately 90%, despite the apparent inability of this inhibitor to exert antiproliferative effects in these cells. These data indicate that BRAF V600E signaling is required for S-phase progression of the cell division cycle in the NZM52 cells.
PIK3CA-mutated melanoma cells are dependent on both MEK1/2 and AKT?mTORC1 signaling for their sustained proliferation AKT is postulated to be a major downstream effector of PI3 0 -lipid signaling in cancer (Pal et al., 2010; She et al., 2010) . Consequently, we examined the dependency of NZM cell proliferation and downstream signaling on AKT activity. To test the effect of single-agent or combined inhibition of MEK1/2 or AKT on cellular proliferation, NZM cells were treated with a MEK1/2 (1 lM GSK1120212/ MEKi 2 ) or AKT (5 lM GSK690693/AKTi) inhibitor, either alone or in combination, with viable cells stained using crystal violet ( Figure 3A) . Single-agent inhibition of MEK1/2 or AKT led to significant decreased cell proliferation of NZM40 (MEKi 2 : P < 0.0005; AKTi: P < 0.005) and NZM91 (MEKi 2 : P < 0.05; AKTi: P < 0.05) cells. Conversely, inhibition of MEK1/2 or AKT displayed only modest antiproliferative effects on NZM52 cells. Intriguingly, while MEK1/2 inhibition with GDC-0973 was previously shown to inhibit NZM52 proliferation, MEK1/2 inhibition with GSK1120212 failed to inhibit NZM52 proliferation to the same extent. However, the combined inhibition of MEK1/2 plus AKT more profoundly suppressed proliferation compared with BYL-719/PI3Kai) inhibitors, either alone or in combination, for 3-8 days with viable cells fixed and stained using crystal violet (above). Quantification of crystal violet staining was assessed by solubilizing the fixed dye and measuring absorbance at k = 562 nm (below). Results are expressed as a fold change of the DMSO control and presented as mean AE SEM of at least three or more independent experiments. Paired, twotailed t tests were performed to determine P values (*P < 0.05; **P < 0.01; ***P < 0.001). (B) NZM cells were treated with inhibitors of MEK1/2 (1 lM GDC-0973/MEKi 1 ), class I PI3K (5 lM GDC-0941/PI3Ki 1 ), or PI3Ka (5 lM BYL-719/PI3Kai), either alone or in combination, for 48 h and pulsed with 10 lM BrdU for the remaining 24 h of drug treatment with BrdU positive cells quantified by flow cytometry. Data are represented as a fold change of BrdU positive cells of the DMSO control and presented as mean AE SEM of at least three or more independent experiments. Oneway ANOVAs were performed to determine P values (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). ( the corresponding single agents in all three NZM cell lines ( Figure 3A) . To examine the effect of combined inhibition of MEK1/2 and AKT on PIK3CA-mutated melanoma cell signaling, NZM cells were treated with single-agent or combined inhibition of MEK1/2 (1 lM GSK1120212/ MEKi 2 ) or AKT (5 lM GSK690693/AKTi) for 24 h with lysates analyzed by immunoblotting ( Figure 3B ). MEK1/2 inhibition led to a substantial decrease in P-ERK1/2 with negligible effects on P-rpS6 or P-4E-BP1 despite the reduction in P-p70 S6K in all three cell lines. By contrast, AKT inhibition greatly enhanced P-AKT, as predicted by this agent's mechanism of action, reduced P-PRAS40, and had little or no effect on Pp70 S6K or P-4E-BP1 Pal et al., 2010; Rhodes et al., 2008) . Although AKT inhibition had negligible effects on P-rpS6 in NZM40 or NZM52 cells, AKT inhibition did reduce P-rpS6 in the NZM91 cell line. Combined MEK1/2 plus AKT inhibition significantly suppressed P-rpS6 in all three cell lines compared with single-agent inhibition of MEK1/2 or AKT, whereas P-4E-BP1 was not further decreased by combined MEK1/2 and AKT inhibition. Together, these data suggest that AKT cooperates with MEK1/2 signaling to regulate the proliferation of the PIK3CA-mutated NZM melanoma cells and to sustain phosphorylation of rpS6. Perhaps surprisingly, inhibition of MEK1/2 or AKT, either alone or in combination, had no discernible effect on the phosphorylation of 4E-BP1 in these NZM cell lines.
To assess a possible role for mTORC1 signaling on PIK3CA-mutated melanoma cell proliferation and the regulation of rpS6 and 4E-BP1 phosphorylation, NZM cells were treated with the mTORC1/2 inhibitor, PP242, (1 or 5 lM mTORi) with cells stained using crystal violet and extracts analyzed by immunoblotting ( Figure 4A, B) . Inhibition of mTORC1/2 at either concentration significantly inhibited NZM cell proliferation as well as P-rpS6 and P-4E-BP1. Inhibition of mTORC1/2 at 5 lM elicited more potent antiproliferative effects and suppression of both P-rpS6 and P-4E-BP1 in all three cells lines compared to 1 lM PP242. Consistent with this data, a ) or AKT (5 lM GSK690693/AKTi), either alone or in combination, for 4-12 days with viable cells fixed and stained using crystal violet (above). Quantification of crystal violet staining was assessed by solubilizing the fixed dye and measuring absorbance at k = 562 nm (below). Data are expressed as a fold change of the DMSO control and presented as mean AE SEM of three independent experiments. Paired, two-tailed t tests were performed to determine P values (*P < 0.05; **P < 0.01; ***P < 0.001). Figure S1A , B) (Pei et al., 2013) . In addition, PP242 or GDC-0349 exhibited the greatest inhibitory effect on mTORC1/2 at 5 lM as evident by the magnitude of the decrease in P-AKT ( Figures 4B and S1B) . Hence, the phosphorylation of rpS6 and 4E-BP1 in the PIK3CA-mutated NZM melanoma cells appears to be dependent on mTORC1 signaling.
In parallel, we assessed whether combined inhibition of MEK1/2 plus mTORC1/2 might provide a more robust inhibition of PIK3CA-mutated melanoma proliferation and signaling. To test the effects of single-agent versus combined MEK1/2 plus mTORC1/2 inhibition, NZM cells were treated with a MEK1/2 (1 lM PD0325901/MEKi 3 ) or mTORC1/2 (5 lM PP242/mTORi) inhibitor, either alone or in combination, with viable cells stained using crystal violet and cell lysates analyzed by immunoblotting (Figure 4C, D) . Similar to the results with the other MEK1/2 inhibitors (GDC-0973 and GSK1120212), MEK1/2 inhibition significantly inhibited the proliferation of NZM40 (P < 0.0001) and NZM91 (P < 0.05) melanoma cells. ) cells were treated with either 1 or 5 lM of the mTORC1/2 inhibitor, PP242 (mTORi), for 4-12 days with viable cells fixed and stained using crystal violet (above). Quantification of crystal violet staining was assessed by solubilizing the fixed dye and measuring absorbance at k = 562 nm (below). Results are expressed as a fold change of the DMSO control and presented as mean AE SEM of three independent experiments. Paired, two-tailed t tests were performed to determine P values (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). (B) All three NZM cell lines were treated with either 1 or 5 lM PP242 (mTORi) for 24 h with extracts analyzed by immunoblotting with the indicated antibodies. (C) NZM40, NZM52, and NZM91 cells were treated with single-agent or combined inhibition of MEK1/2 (1 lM PD0325901/MEKi 3 ) or mTORC1/2 (5 lM PP242/mTORi) for 4-11 days with viable cells fixed and stained using crystal violet. Crystal violet staining was quantified as described above. Results are expressed as a fold change of the DMSO control and presented as mean AE SEM of three independent experiments. Paired, two-tailed t tests were performed to determine P values (*P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001). However, PD0325901 had no discernible effect on NZM52 proliferation, which is consistent with the lack of antiproliferative effects of GSK1120212 on these cells. Although mTORC1/2 inhibition potently suppressed NZM proliferation, MEK1/2 inhibition did not substantially enhance the antiproliferative effects of mTORC1/2 inhibition. As previously demonstrated, MEK1/2 inhibition led to decreased P-p70 S6K and P-ERK1/2 with little or no effect on P-AKT, P-PRAS40, P-rpS6, or P-4E-BP1. Conversely, mTORC1/2 inhibition suppressed P-AKT, P-PRAS40, P-rpS6, and P-4E-BP1, but did not reduce P-ERK1/2 or P-p70 S6K levels. Combined MEK1/2 and mTORC1/2 inhibition exhibited cooperative effects on PrpS6, whereas P-4E-BP1 was not further diminished compared with single-agent mTORC1/2 inhibition. Thus, the coordinate control of mTORC1 by MEK1/2 and PI3K signaling appears to be important for regulating the proliferation of NZM melanoma cell proliferation through effects on rpS6 and 4E-BP1 phosphorylation.
Combination MEK1/2 plus b-sparing PI3K inhibition inhibits tumorigenesis of xenografted NRAS Q61H / PIK3CA H1047R -mutated cells It has recently been demonstrated that, compared to single-agent blockade, combined inhibition of MEK1/2 and PI3Ka signaling significantly enhanced the durability of the response of BRAF V600E /PIK3CA H1047R -driven mouse melanomas to pathway-targeted inhibition (Deuker et al., 2015) . These results, combined with the antiproliferative activity of combined MEK1/2 plus either the PI3Ka (BYL-719) implantation of NZM40 (NRAS Q61H /PIK3CA H1047R ) cells into immunocompromised mice. NZM40 cells were injected subcutaneously into nude mice and, 3 weeks after injection when tumors had grown to approximately 600 mm 3 ( Figure 5A ) or 230 mm 3 ( Figure 5B ), mice were randomized to receive vehicle, GDC-0973 (2 or 4 mg/kg, once a day/MEKi 1 ), BYL-719 (50 mg/kg twice a day/ PI3Kai), GDC-0032 (6 mg/kg, once a day/PI3Ki 2 ), or the combination of GDC-0973 plus either BYL-719 or GDC-0032 treatment ( Figure 5A , B, respectively). It should be noted that mice dosed at 4 mg/kg with GDC-0973 in combination with the b-sparing PI3K inhibitor, GDC-0032, led to severe toxicity issues in the NZM40-xenografted mice. Therefore, to dose the mice in combination with the MEK1/2 and b-sparing PI3K inhibitors without eliciting substantial toxicities, mice were treated with 2 mg/kg of the MEK1/2 inhibitor. Target inhibition of the various signaling pathways was assessed by immunoblot analyses of tumor cell lysates (Figure S2A-D) . In brief, combined inhibition of MEK1/2 and either PI3Ka or bsparing PI3K led to a greater decrease in P-AKT, P-PRAS40, P-p70 S6K , P-rpS6, and P-4E-BP1 compared with the corresponding single agents.
Consistent with previously published reports, single-agent MEK1/2 inhibition failed to elicit melanoma regression, and only modestly attenuated tumor growth ( Figure 5A , B) (Kwong et al., 2012; Posch et al., 2013) . The lack of efficacy of single-agent treatment with the MEK1/2 inhibitor may be due to insufficient target coverage of aberrant NRAS Q61H ?RAF?MEK1/2? ERK1/2 signaling at these concentrations, which was further substantiated by the inability of the MEK1/2 inhibitor to fully suppress P-ERK1/2 levels ( Figure S2A and S2B). Treatment of melanoma bearing mice with either the PI3Ka or b-sparing PI3K inhibitors elicited significant tumor growth inhibition compared to MEK1/2 monotherapy (PI3Ka: P < 0.0001; PI3Ki 2 : P < 0.005), but this effect was largely cytostatic and did not promote tumor regression. Importantly, the combination of MEK1/ 2 plus b-sparing PI3K inhibitor resulted in more potent tumor regression than achieved with either MEK1/2 or bsparing PI3K monotherapy ( Figure 5B, D) . By contrast, combined MEK1/2 plus PI3Ka inhibition induced more profound tumor growth inhibition as compared to MEK1/2 monotherapy (P < 0.0001). However, the combination of MEK1/2 plus the PI3Ka inhibitor did not significantly enhance the antitumor effects of the PI3Ka inhibitor ( Figure 5A ). The analysis of the best overall responses revealed that only one of seven mice treated with the combination of MEK1/2 and PI3Ka inhibition displayed greater than 30% melanoma regression, which scores as a partial response by modified response evaluation criteria in solid tumors (RECIST) 1.1 guidelines ( Figure 5C ) (Eisenhauer et al., 2009) . By contrast, four of six mice treated with the combination of MEK1/2 plus b-sparing PI3K inhibitors achieved a partial response by modified RECIST guidelines ( Figure 5D ).
Discussion
Malignant transformation of melanocytes is thought to be promoted by the accrual of genetic alterations in key signaling pathways that cooperate in the initiation and progression of melanoma cells (Chin et al., 1997 (Chin et al., , 1998 Dhomen et al., 2009; Goel et al., 2006; Gray-Schopfer et al., 2005; Haluska et al., 2006; Hodis et al., 2012; Vredeveld et al., 2012) . Although mutational activation of BRAF can promote benign proliferation of melanocytes resulting in nevus formation, cooperating alterations in additional pathways are required for progression to melanoma (Cancer Genome Atlas, 2015; Dankort et al., 2009; Deuker et al., 2015; Goel et al., 2006; Haluska et al., 2006; Hodis et al., 2012; Marsh Durban et al., 2013; Vredeveld et al., 2012) . Thus, the components of the PI3K signaling pathway, which controls PI3 0 -lipid accumulation, are frequently mutated in melanoma cells. PI3
0 -lipid accumulation in melanoma cells can be promoted by silencing of the PTEN tumor suppressor or through mutational activation of PIK3CA or RAC1, the last of which is reported to activate PI3Kb (Cancer Genome Atlas, 2015; Curtin et al., 2006; Fritsch et al., 2013; Hodis et al., 2012; Kim et al., 2012; Omholt et al., 2006; Samuels and Velculescu, 2004; Shull et al., 2012) . However in melanoma, as in other cancers, a critical question is the extent to which mutational alterations of components of PI3 0 -lipid signaling predicts for therapeutic responses to inhibitors of PI3 0 -kinases or its direct downstream effectors such as the AKT, serum-and glucocorticord-inducible protein kinase (SGK), or other effectors of PI3 0 -lipid signaling (Cancer Genome Atlas, 2015; Hodis et al., 2012; She et al., 2010; Tessier and Woodgett, 2006; Vanhaesebroeck et al., 2012; Vasudevan et al., 2009) . In genetically engineered mouse models, BRAF V600E cooperates with either PTEN silencing or mutational activation of PIK3CA for melanomagenesis, however, pharmacological inhibition of PI3 0 -lipid accumulation in these cells fails to elicit melanoma regression resulting in largely cytostatic effects (Dankort et al., 2009; Deuker et al., 2015; Marsh Durban et al., 2013) . However, inhibitors of PI3K forestalled the onset of resistance to agents that target BRAF V600E signaling in these GEM models (Deuker et al., 2015) .
In this study, using PIK3CA-mutated metastatic melanoma cell lines, we showed that such cells were sensitive to pharmacological inhibition of PI3K signaling. Moreover, these cells were also sensitive to combined blockade of both MEK1/2 and PI3K signaling. This suggests that PIK3CA-mutated melanoma cell lines have a dependency on both MEK1/2 and PI3K signaling for their maintenance. Despite containing a PIK3CA mutation, both PI3 0 -lipid signaling and NZM cell proliferation were more sensitive to more broad spectrum PI3K inhibitors than to an aselective PI3K inhibitor. These data suggest that, at least in vitro, more than one isoform of PI3K is contributing to the PI3 0 -lipid accumulation in these cells. The importance of BRAF V600E signaling in melanoma maintenance is emphasized by the clinical success of BRAF V600E inhibitors to elicit potent tumor regression in BRAF-mutated melanoma patients with advanced disease (Chapman et al., 2011; Flaherty et al., 2010) . Moreover, both in vitro and in vivo, BRAF V600E /PIK3CA H1047R -driven mouse melanomas and their derivative cell lines were sensitive to pathway-targeted blockade of either BRAF V600E or PIK3CA H1047R (Deuker et al., 2015; Marsh Durban et al., 2013) . Although NZM52 (BRAF V600E /PIK3-CA H1047R ) cells were sensitive to MEK1/2 inhibition, it was surprising that these cells appeared to be largely resistant to BRAF V600E inhibition despite the substantial effect of BRAF V600E inhibition to suppress S-phase progression in these cells. The lack of antiproliferative effects of BRAF V600E inhibition may be explained by the apparent reactivation of MEK1/2?ERK1/2 signaling at later time points following drug addition. Moreover, we cannot exclude the possibility that these cells may also be activating alternative signaling mechanisms downstream of ERK1/2 in a manner that was not revealed by our targeted next-generation genomic sequencing of these cells.
We have previously reported that several human BRAFmutated melanoma cell lines are largely insensitive to either allosteric or conventional ATP-competitive inhibitors of AKT (Marsh Durban et al., 2013; . Here we report that single-agent inhibition of AKT had only modest effects on the proliferation of the PIK3CA-mutated NZM melanoma cell lines, but cooperated with MEK1/2 inhibition for robust suppression of NZM cell proliferation. This is consistent with the sensitivity of GEM models of BRAF V600E /PIK3CA
H1047R mouse melanomas and cell lines to AKT inhibition and its ability to effectively suppress growth (Marsh Durban et al., 2013) . Inhibition of the PI3K?AKT signaling axis is predicted to inhibit the mTORC1 downstream signaling effectors p70 S6K , rpS6, and 4E-BP1 (Zoncu et al., 2011) . Our data revealed that phosphorylation of p70 S6K appears to be largely under the control MEK1/2 signaling in the NZM cell lines, as we have previously observed in other melanoma cells, whereas rpS6 phosphorylation appears to be under coordinate control of both the MEK1/2 and PI3K signaling axes . By contrast, the phosphorylation of 4E-BP1, a regulator of cap-dependent translation initiation, was sensitive to PI3K inhibition, but largely resistant to the inhibition of either MEK1/2 or AKT signaling. This is consistent with recent data indicating the existence of a PDK1?SGK signaling axis that regulates mTORC1 activity independently of AKT and engenders resistance to PI3K inhibitors (Castel et al., 2016) . In previous work, we and others have inferred the importance of the coordinate control of mTORC1 by both MAPK and PI3K signaling as being essential for melanoma cell proliferation. Our data demonstrate that the NZM melanoma cells were sensitive to mTORC1/2 inhibition as evident by the profound decrease in rpS6 and 4E-BP1 phosphorylation and cell proliferation. However, the effect of mTORC1/2 inhibition was not potentiated by pharmacological inhibition of MEK1/2 signaling. These data further reinforce the importance of mTORC1/2 as a target for suppression of melanoma cell proliferation (Gowrishankar et al., 2012; .
Despite the antiproliferative effects of either the bsparing PI3K or PI3Ka inhibitor on the proliferation of NZM40 (NRAS Q61H /PIK3CA H1047R ) melanoma cells in vitro, these agents elicited largely cytostatic effects on NZM40-xenografted tumors. Although combined inhibition of MEK1/2 plus b-sparing PI3K displayed significant cooperation in reducing tumor growth compared to the corresponding single agents, the ability of this combination to elicit tumor regression was quite modest and transient. The inability of this combined treatment to promote tumor regression may be reflected in the fact that we did not observe evidence of NZM40 cell death in vitro, even though the combined blockade of MEK1/2 plus PI3K signaling potently inhibited DNA synthesis. It is possible that the dosing regimen(s) did not provide adequate target coverage of NRAS Q61H ?RAF?MEK1/ 2?ERK1/2 or PI3 0 -lipid signaling in these tumors, and therefore, we are unable to propose that these data provide a compelling rationale for the deployment of PI3K inhibitors for the treatment of those rare patients whose melanomas express mutationally activated PIK3CA.
Methods
Cell culture and drug treatments Human melanoma cell lines NZM40, NZM52, and NZM91 were maintained as previously described (Table S1 ) (Kim et al., 2012) . Confirmation of the various gene mutations in BRAF, NRAS, or PIK3CA was performed by the UCSF Clinical Cancer Genomics Laboratory using next-generation genomic sequencing, in which the mutational status of approximately 500 cancer-relevant genes was assessed (http://cancer.ucsf.edu/intranet/ccgl). Pathwaytargeted pharmacological inhibitors of intracellular signaling were obtained from various colleagues in the private sector or from commercial sources (Barrett et al., 2008; Feldman et al., 2009; Folkes et al., 2008; Furet et al., 2013; Gilmartin et al., 2011; Heerding et al., 2008; Ndubaku et al., 2013; Pei et al., 2013; Rice et al., 2012; Stuart et al., 2012) . Drug concentrations used for each treatment are listed in Table S2 .
Cell proliferation assays Melanoma cell proliferation was assessed by seeding 5 9 10 4 cells in six-well plates or 2 9 10 4 cells in 12-well plates. Cells were cultured in the absence or presence of the various pharmacological agents for 4-21 days, at which time viable cells were fixed and stained using crystal violet. To quantify cellular proliferation, crystal violet stained cells were solubilized in 33% acetic acid with absorbance measured at 562 nm.
Transit of cells through S-phase was assessed by measurement of bromodeoxyuridine (BrdU) incorporation and DNA content using the FITC BrdU Flow Kit (BD Pharmingen) according to the manufacturer's instructions. Cells seeded at a density of 1-3 9 10 5 cells/well in six-well plates were treated with the various pharmacological agents for 48 h and then labeled with 10 lM BrdU for the remaining 24 h of the drug treatment. BrdU labeled cells were fixed and stained with FITC-conjugated anti-BrdU antibody and 7-aminoactinomycin D (7-AAD) and then analyzed by two-color flow cytometry. Quantification of BrdU positive cells was performed using FLOWJO v.10.0.8 software.
Immunoblot analysis
Cell lysates were prepared for immunoblot analysis as previously described . Membranes were probed with the primary antibodies as described in Table S3 . Antigen-antibody complexes were detected using fluorescent goat antiRabbit or anti-Mouse IRDye 800 or goat anti-Mouse IRDye 680 secondary antibodies (LI-COR Biosciences) and visualized using a LI-COR Odyssey Classic infrared imaging system. Immunoblot data were analyzed using the Odyssey application software v3.0.30 software (LI-COR Biosciences) .
Xenograft tumor studies in immunocompromised mice
The University of California, San Francisco Institutional Animal Care and Use Committee (IACUC) reviewed and approved all animal procedures. Four-to six-week-old athymic nude female mice were subcutaneously injected with 5 9 10 6 to 1 9 10 7 NZM40 human melanoma cells suspended in Matrigel. In the case of GDC-0973 plus GDC-0032 inhibitor study, drug treatment was initiated when the mean tumor volume exceeded approximately 230 mm 3 . For the GDC-0973 plus BYL-719 inhibitor study, drug treatment was initiated when the tumor volume was approximately 600 mm 3 . At this point, mice were divided among the treatment arms to give an equal distribution of tumor volume. Mice were assigned to receive vehicle; BYL-719 (50 mg/kg, b.i.d.) formulated in 0.5% carboxymethylcellulose/0.5% Tween-80; GDC-0973 (2 mg/kg for GDC-0973/GDC-0032 treatment or 4 mg/kg for GDC-0973/BYL-719 treatment, q.d.) or GDC-0032 (6 mg/kg, q.d.) both formulated in 0.5% methylcellulose/0.2% Tween-80; either as single agents or in combination and administered via oral gavage 5 days per week. Melanoma growth was measured weekly using digital calipers with relative tumor volume (RTV) estimated using the ellipsoid volume formula as described previously (Marsh Durban et al., 2013) . Animals were euthanized based on a body conditioning score (BCS≤2) as described (Ullman-Cullere and Foltz, 1999) or when the tumor volume exceeded ≥2 cm 3 , whichever occurred first. At necropsy, tissue was snap-frozen in liquid nitrogen and homogenized in RIPA buffer using the Tissue Lyser II (Qiagen). Immunoblot analyses were performed as previously described .
Statistical analysis
All quantitative data are represented as mean AE SEM of at least three or more independent experiments. GraphPad Prism 6 statistical software was used to determine P values by performing paired, two-tailed t tests or one-way or two-way ANOVAs as indicated. Zoncu, R., Efeyan, A., and Sabatini, D.M. (2011) . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35.
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